NCT06148389View on ClinicalTrials.gov

The Safety and Tolerability of STSA-1301 Subcutaneous Injection in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

November 16, 2023

Primary Completion Date

April 3, 2024

Study Completion Date

April 3, 2024

Conditions
Primary Immune Thrombocytopenia
Interventions
DRUG

STSA-1301 subcutaneous injection

Subjects will receive the administration dose on Day 0 following protocol requirements.

DRUG

Placebo

Subjects will receive the administration dose on Day 0 following protocol requirements.

Trial Locations (1)

100015

Beijing Ditan Hospital,Capital Medical University, Beijing

All Listed Sponsors
lead

Staidson (Beijing) Biopharmaceuticals Co., Ltd

INDUSTRY

NCT06148389 - The Safety and Tolerability of STSA-1301 Subcutaneous Injection in Healthy Subjects | Biotech Hunter | Biotech Hunter